Synthesis and applications of silver nanoparticles

AbstractOver the past few decades, nanoparticles of noble metals such as silver exhibited significantly distinct physical, chemical and biological properties from their bulk counterparts. Nano-size particles of less than 100nm in diameter are currently attracting increasing attention for the wide range of new applications in various fields of industry. Such powders can exhibit properties that differ substantially from those of bulk materials, as a result of small particle dimension, high surface area, quantum confinement and other effects. Most of the unique properties of nanoparticles require not only the particles to be of nano-sized, but also the particles be dispersed without agglomeration. Discoveries in the past decade have clearly demonstrated that the electromagnetic, optical and catalytic properties of silver nanoparticles are strongly influenced by shape, size and size distribution, which are often varied by varying the synthetic methods, reducing agents and stabilizers. Accordingly, this review presents different methods of preparation silver nanoparticles and application of these nanoparticles in different fields

Synthesis of New Coumarin Derivatives Used as Nitrification Inhibitors to Mitigation of Nitrous Oxide Emission from Agricultural Soil.

Nitrous oxide (N2O) is one of the major greenhouse gases "GHG” the main source of N2O emission is synthetic mineral nitrogen fertilizers. The conversion values according to the global warming potential for N2O are 298 times as CO2 per molecule. The main objective of this work is to mitigate GHG emission from N2O by create synthesis new nitrification inhibitors.  Coumarine derivatives were synthesized (1-4), and prove the structures by spectral data, the compounds (1) and (4) were applied as nitrification inhibitors to mitigation of nitrous oxide. The results indicated that, the presence of each of the two tested inhibitors (1, 4) reduced the N2O emission from urea-treated soils by 72% and 49%, respectively, in inhibiting nitrification during the 28-day incubation period. Key words: Nitrous oxide emissions, Mitigation, Agricultural soil, Nitrification, Coumarin derivatives

ARIA 2016 Executive Summary Integrated care pathways for predictive medicine across the life cycle

The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization (WHO) workshop in 1999. The initial goals were (i) to propose a new allergic rhinitis classification, (ii) to promote the concept of multi-morbidity in asthma and rhinitis and (iii) to develop guidelines with all stakeholders for global use in all countries and populations. ARIA - disseminated and implemented in over 70 countries globally - is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK (MACVIA (Contre les MAladies Chroniques pour un VIeillissement Actif)-ARIA Sentinel NetworK) uses mobile technology to develop care pathways in order to enable the management of rhinitis and asthma by a multi-disciplinary group or by patients themselves. An App (Android and iOS) is available in 20 countries and 15 languages. It uses a visual analogue scale to assess symptom  control and work productivity as well as a clinical decision support system. It is associated with an inter-operable tablet for physicians and other health care professionals. The scaling up strategy uses the recommendations of the European Innovation Partnership on Active and Healthy Ageing. The aim of the novel ARIA approach is to provide an active and healthy life to rhinitis sufferers, whatever their age, sex or socio-economic status, in order to reduce health and social inequalities incurred by the disease.Keywords: ARIA, rhinitis, ICT, EIP on AHA, mobile technology, AIRWAYS ICP

Ethyl acetate extract of Ceiba pentandra (L.) Gaertn. reduces methotrexate-induced renal damage in rats via antioxidant, anti-inflammatory, and antiapoptotic actions

Methotrexate (MTX) is a chemotherapeutic agent and an immunosuppressant used to treat cancer and autoimmune diseases. However, its use is limited by its multi-organ toxicity, including nephrotoxicity, which is related to MTX-driven oxidative stress. Silencing oxidative stressors is therefore an important strategy in minimizing MTX adverse effects.Medicinal plants rich in phenolic compounds are probable candidates to overcome these oxidants. Herein, C. pentandra ethyl acetate extract showed powerful in vitro radical-scavenging potential (IC50 = 0.0716) comparable to those of the standard natural (ascorbic acid, IC50 = 0.045) and synthetic (BHA, IC50 = 0.056) antioxidants. The effect of C. pentandra ethyl acetate extract against MTX-induced nephrotoxicity in rats was evaluated by administering the extract (400 mg/kg/day) or the standard antioxidant silymarin (100 mg/kg/day) orally for 5 days before and 5 days after a single MTX injection (20 mg/kg, i.p.).C. pentandra showed slight superiorities over silymarin in restoring the MTX-impaired renal functions, with approximately twofold decreases in overall kidney function tests. C. pentandra also improved renal antioxidant capacity and reduced the MTX-induced oxidative stress. Moreover, C. pentandra inhibited MTX-initiated apoptotic and inflammatory cascades, and attenuated MTX-induced histopathological changes in renal tissue architecture.Phytochemical investigation of the extract led to the purification of the phenolics quercitrin (1), cinchonains 1a (2) and 1b (3), cis-clovamide (4), trans-clovamide (5), and glochidioboside (6); a structurally similar with many of the reported antioxidant and nephroprotective agents. In conclusion, these data demonstrate that C. pentandra exhibits nephroprotective effect against MTX-induced kidney damage via its antioxidant, antiapoptotic and anti-inflammatory mechanisms. TaxonomyFunctional Disorder, Traditional Medicine, Herbal Medicine

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Diagnosis of obstructive coronary artery disease using computed tomography angiography in patients with stable chest pain depending on clinical probability and in clinically important subgroups: Meta-analysis of individual patient data

Objective To determine whether coronary computed tomography angiography (CTA) should be performed in patients with any clinical probability of coronary artery disease (CAD), and whether the diagnostic performance differs between subgroups of patients. Design Prospectively designed meta-analysis of individual patient data from prospective diagnostic accuracy studies. Data sources Medline, Embase, and Web of Science for published studies. Unpublished studies were identified via direct contact with participating investigators. Eligibility criteria for selecting studies Prospective diagnostic accuracy studies that compared coronary CTA with coronary angiography as the reference standard, using at least a 50% diameter reduction as a cutoff value for obstructive CAD. All patients needed to have a clinical indication for coronary angiography due to suspected CAD, and both tests had to be performed in all patients. Results had to be provided using 2×2 or 3×2 cross tabulations for the comparison of CTA with coronary angiography. Primary outcomes were the positive and negative predictive values of CTA as a function of clinical pretest probability of obstructive CAD, analysed by a generalised linear mixed model; calculations were performed including and excluding non-diagnostic CTA results. The no-treat/treat threshold model was used to determine the range of appropriate pretest probabilities for CTA. The threshold model was based on obtained post-test probabilities of less than 15% in case of negative CTA and above 50% in case of positive CTA. Sex, angina pectoris type, age, and number of computed tomography detector rows were used as clinical variables to analyse the diagnostic performance in relevant subgroups. Results Individual patient data from 5332 patients from 65 prospective diagnostic accuracy studies were retrieved. For a pretest probability range of 7-67%, the treat threshold of more than 50% and the no-treat threshold of less than 15% post-test probability were obtained using CTA. At a pretest probability of 7%, the positive predictive value of CTA was 50.9% (95% confidence interval 43.3% to 57.7%) and the negative predictive value of CTA was 97.8% (96.4% to 98.7%); corresponding values at a pretest probability of 67% were 82.7% (78.3% to 86.2%) and 85.0% (80.2% to 88.9%), respectively. The overall sensitivity of CTA was 95.2% (92.6% to 96.9%) and the specificity was 79.2% (74.9% to 82.9%). CTA using more than 64 detector rows was associated with a higher empirical sensitivity than CTA using up to 64 rows (93.4% v 86.5%, P=0.002) and specificity (84.4% v 72.6%, P<0.001). The area under the receiver-operating-characteristic curve for CTA was 0.897 (0.889 to 0.906), and the diagnostic performance of CTA was slightly lower in women than in with men (area under the curve 0.874 (0.858 to 0.890) v 0.907 (0.897 to 0.916), P<0.001). The diagnostic performance of CTA was slightly lower in patients older than 75 (0.864 (0.834 to 0.894), P=0.018 v all other age groups) and was not significantly influenced by angina pectoris type (typical angina 0.895 (0.873 to 0.917), atypical angina 0.898 (0.884 to 0.913), non-anginal chest pain 0.884 (0.870 to 0.899), other chest discomfort 0.915 (0.897 to 0.934)). Conclusions In a no-treat/treat threshold model, the diagnosis of obstructive CAD using coronary CTA in patients with stable chest pain was most accurate when the clinical pretest probability was between 7% and 67%. Performance of CTA was not influenced by the angina pectoris type and was slightly higher in men and lower in older patients. Systematic review registration PROSPERO CRD42012002780

Comparative morphological and biological studies of two rhagidiid mites: Robustocheles deltacus and Rhagidia qaliubiensis

International audienceThe two rhagidiid species: Robustocheles (R.) deltacus and Rhagidia (R.) qaliubiensis were able to develop successfully from egg to adult on different fungal diets, but failed to lay eggs. When they were reared on larvae of cotton springtail Lepidocenitus insertus (Hand.), larvae of housefly Musca domestica L. and immatures of the tydeid soil mite Tydeus aegyptiaca (Rasmy and El-Bagoury), they laid eggs. They passed through egg, larvae, proto-, deuto-, tritonymph and adult stages. The durations of the immature and adult stages, as well as life table parameters were determined. Feeding on L. insertus gave the highest reproductive rate as compared to that on M. domestica and T. aegyptiaca. Ontogenetic setal development in the comparative study of the life stages of the two rhagidiid species indicated that the dorsal idiosomal chaetotaxy and the number of anal setae remained unchanged throughout the life cycle; a single adanal pair appears only in R. (R.) qaliubiensis protonymph and its successive stages. The increase in genital flap length at each moult is accompained by an increase in the number of setae situated on the flaps and the number of setae provides the simplest method of separating the nymphal stages. Patterns of leg chaetotaxy and solenidia also provide a method to separate nymphal stages

Effect of dietary sage (Salvia officinalis L.) on the growth performance, feed efficacy, blood indices, non-specific immunity, and intestinal microbiota of European sea bass (Dicentrarchus labrax)

Adding medicinal herbs to aquafeed is recommended for feasible aquaculture activity. This study tested for 90 days the effect of dietary sage (Salvia officinalis L.) on the growth performance, feed efficacy, blood indices, non-specific immunity, and intestinal microbiota of European sea bass (Dicentrarchus labrax; n = 300 fish). Fish with an initial weight of 12 ± 0.1 g/fish were distributed in five treatments and fed sage at 0, 2, 4, 6, and 8 mg/kg. Dietary sage at 2 g/kg diet improved the growth, feed consumption, and growth hormone secretion in European sea bass. The blood parameters in European sea bass fed on experimental diets showed normal levels for healthy fish. Significantly higher lysozyme and phagocytic activities were recorded with sage supplement at the 4 g/kg diet compared to other groups. Regarding overall bacterial count, fish given a sage-free diet (the control) showed more significant microbiota numbers, Vibrio, Escherichia coli, and acid-fermentative bacteria. Remarkably, fish fed on diets fortified with sage displayed lower records of the total bacterial count, Vibrio, and Escherichia coli than the control. Moreover, fish fed a diet enriched with high levels of sage (6 or 8 g/kg) showed increased acid-fermentative bacteria. The regression analysis showed that the optimum quantity of sage at 3.6 – 4.1 g/kg diet is recommended based on the weight gain, specific growth rate (SGR), phagocytic activity, feed conversion ratio (FCR), and lysozyme activity. In conclusion, the dietary incorporation of sage (2 – 4 g/ kg diet) enhanced growth, feed efficacy, blood indices, non-specific immune responses, and sustained healthier gut flora in European sea bass